Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

NCT00953420 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Dexamethasone
BIOLOGICAL: EBV-specific cytotoxic T lymphocytes
BIOLOGICAL: G-CSF or Peg-GCSF

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]
[object Object]